(NASDAQ: TVGN) Tevogen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 64.19%.
Tevogen's earnings in 2026 is -$22,141,244.On average, 3 Wall Street analysts forecast TVGN's earnings for 2026 to be -$63,096,823, with the lowest TVGN earnings forecast at -$60,622,437, and the highest TVGN earnings forecast at -$64,952,612. On average, 3 Wall Street analysts forecast TVGN's earnings for 2027 to be -$86,343,020, with the lowest TVGN earnings forecast at -$82,957,020, and the highest TVGN earnings forecast at -$88,882,521.
In 2028, TVGN is forecast to generate $102,947,447 in earnings, with the lowest earnings forecast at $98,910,293 and the highest earnings forecast at $105,975,314.